clinical trial · NCT07178912
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center·phase2·not yet recruiting·n = 60
Phase II Clinical TrialBlinatumomabOlverembatinibLymphoblastic LeukemiaPhiladelphia Chromosome PositiveBlinatumomabolverembatinib
brief summary
To find out if giving blinatumomab as injections under the skin and olverembatinib can help to control the disease in patients with Ph-positive ALL.
started
Aug 27, 2026
primary completion
Sep 30, 2031
completion
Sep 30, 2033
last updated
Mar 9, 2026
detailed description
Primary Objective
• To evaluate the rate of complete molecular response (CMR; undetectable BCR::ABL1 transcript by RT-PCR) in participants with newly diagnosed Ph-positive ALL and the overall response rate (complete remission + complete remission with incomplete count recovery) in participants with relapsed/refractory Ph-positive ALL
Secondary Objectives
* To evaluate event-free survival (EFS) * To evaluate overall survival (OS) * To evaluate MRD negativity by next-generation sequencing (NGS) at a sensitivity of 1x10-6 * To assess the safety of the regimen
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol